was zolpidem fda approved in 1992 for short-term treatment of insomnia? yes
“It was FDA approved in 1992 for short-term treatment of insomnia.”
a host said on Psychopharmacology and Psychiatry Updates, 2026-10-18, at 01:45. hear it in context →
the episode: Are Z-Drugs Safe in the First Trimester of Pregnancy? (at 01:45). we link the show's own page; we do not re-host audio.
first, the part that holds
The claim holds as stated. The FDA approval record shows zolpidem was first approved on december 16, 1992, and every FDA label we read gives "short-term treatment of insomnia" as its indication.
what we found when we went and looked
We read the FDA's Drugs@FDA record for the original zolpidem application, NDA 019908. It lists an original approval date of december 16, 1992, classed as a new molecular entity. The FDA-approved labels from 2007 and 2022 both say "Initial U.S. Approval: 1992" and both say zolpidem "is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation." One detail the claim leaves out: since at least 2007 the label has limited the indication to trouble falling asleep, and it says efficacy was shown in trials 4-5 weeks long. That narrowing doesn't make the claim wrong.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| zolpidem was FDA approved in 1992 | confirmed | Drugs@FDA lists NDA 019908 (zolpidem tartrate tablets) with an original approval date of december 16, 1992, type 1 new molecular entity, standard review. The 2007 and 2022 labels both print "Initial U.S. Approval: 1992." [1][2][3] |
| the approval was for short-term treatment of insomnia | confirmed | Both labels we read open the indications section with "indicated for the short-term treatment of insomnia," followed by "characterized by difficulties with sleep initiation." The 2022 label adds "Long-term use of AMBIEN is not recommended. Treatment should be as short as possible." We did not read the 1992 label itself. Every label we did read gives short-term treatment as the indication. [2][3] |
| the 1992 indication was worded the same as today's (short-term insomnia with sleep-onset difficulty) | unverifiable | Under 'recent major changes', the 2007 label lists 'Indications and Usage (1) 03/2007', so the indication wording was revised in 2007. The 1992 approval letter and label are not on the FDA pages we fetched, so we could not compare the original wording with the 2007 version. The speaker did not make this claim. We include it as context. [3] |
| 'short-term' on the label is backed by trials of a specific length | confirmed | Both labels say zolpidem "has been shown to decrease sleep latency for up to 35 days in controlled clinical studies" and that "the clinical trials performed in support of efficacy were 4-5 weeks in duration." The 2007 label says failure of insomnia to remit after 7 to 10 days of treatment "may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated." This is context, not part of the speaker's claim. [2][3] |
both directions
for the speaker: The FDA's own approval history gives 1992 as the year of first approval (december 16, 1992, NDA 019908). Both labels we read print "Initial U.S. Approval: 1992" and give short-term treatment of insomnia as the indication. The 2022 label goes further: it says long-term use is not recommended and treatment should be as short as possible.
against: Nothing in the record we read contradicts the claim. The one gap is detail. Since at least 2007 the label has been narrower than "insomnia" in general: it says insomnia "characterized by difficulties with sleep initiation." The 2007 label also shows the indications section was revised that year. So today's wording may not match the 1992 wording, and the speaker's version is a fair summary rather than a quotation of any one label.
what this cannot say
We did not find or read the original 1992 approval letter or the 1992 label. Drugs@FDA does not post them for this application, so the 1992 indication wording comes from the later labels, not the original document. The approval date comes from the Drugs@FDA database entry. We checked the immediate-release tablet application only. Later zolpidem products, such as the extended-release, sublingual and oral spray forms, have their own approval dates and indications. The claim does not cover those, and neither did we.
sources, each one fetched and read
- U.S. Food and Drug Administration, Drugs@FDA, NDA 019908 (zolpidem tartrate) application overview and approval history What we read there: Original approval date december 16, 1992; chemical type 1 – new molecular entity; standard review; later labeling supplements through 2022 (SUPPL-47, february 23, 2022). Fetched 2026-10-19 (HTTP 200). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019908
- U.S. Food and Drug Administration, zolpidem tartrate tablets prescribing information, NDA 019908, revised 2/2022 What we read there: "Initial U.S. Approval: 1992"; "indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. ... shown to decrease sleep latency for up to 35 days in controlled clinical studies"; "Long-term use ... is not recommended. Treatment should be as short as possible." Fetched 2026-10-19 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019908s40s044s047lbl.pdf
- U.S. Food and Drug Administration, zolpidem tartrate tablets prescribing information, NDA 019908 S-022, 2007 What we read there: "Initial US Approval: 1992"; recent major changes lists "Indications and Usage (1) 03/2007"; "indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation"; "The clinical trials performed in support of efficacy were 4-5 weeks in duration"; failure of insomnia to remit after 7 to 10 days "may indicate the presence of a primary psychiatric and/or medical illness." Fetched 2026-10-19 (HTTP 200). https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019908s022lbl.pdf
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam